Co-Diagnostics Inc (NASDAQ:CODX) has announced the appointment of Mark Poritz as the company's new chief scientific officer (CSO).
Poritz is a Harvard University-educated molecular biologist with more than 30 years of experience in the application of polymerase chain reaction (PCR) and related methods to gene cloning, drug discovery, infectious disease diagnostics and aptamer selection.
“Mark has made many notable contributions to molecular diagnostics in a career that has spanned decades, and we expect the impact he will make in advancing of our vision of increasing the accessibility of state-of-the-art molecular diagnostic solutions will be felt immediately,” Co-Diagnostics CEO Dwight Egan said in a statement.
READ: Co-Diagnostics ends 2Q with $96M in cash, expands infectious disease testing menu to include monkeypox
“We also extend our gratitude to our outgoing CSO Jesse Montgomery, PhD, for the contributions he has made to Co-Diagnostics and wish him well in his future endeavors,” Egan added.
Poritz has most recently served as the CSO of Idaho Molecular, the subsidiary acquired by Co-Dx at the end of 2021, and has been actively involved with the development of its upcoming Co-Dx PCR Home testing platform.
Utah-based Co-Diagnostics is a molecular diagnostics company that develops, manufactures and markets new, state-of-the-art diagnostics technologies. The company's technology is used for tests designed using the detection and/or analysis of nucleic acid molecules: DNA or RNA.
Co-Diagnostics also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.
Contact Sean at sean@proactiveinvestors.com